PAREXEL International Experts to Share Key Industry Insights at Drug Information Association 46th Annual Meeting

BOSTON, June 10 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, today announced that several of its experts will present on important industry issues at the Drug Information Association (DIA) 46th Annual Meeting, being held from June 13 17, 2010 in Washington, DC. PAREXEL thought leaders will address key topics including accessing global and emerging markets, reimbursement strategies, comparative effectiveness, centralized monitoring, and study feasibility assessment processes, as well as development strategies for biologics and clinical and regulatory requirements for combination products. Experts will also discuss best practices for leveraging technology to drive productivity and simplify supplies forecasting, as well as study implementation using clinical trial technologies.

Complimentary white papers with insights into key aspects of biosimilar development will be provided at PAREXEL's Booth #917 in the exhibit hall. The white papers, authored by Cecil Nick, B.Sc. (Hons), Vice President, Biotechnology and Bruce Babbitt, Ph.D., Principal Consultant, both of PAREXEL Consulting, are respectively entitled "How Can The Biosimilar Concept Be Applied to More Complex Proteins Such as Monoclonals" and "The Dawn of Biosimilar Development in the U.S.: Key Legislative Aspects and Next Steps for Biopharma Manufacturers."

A global team of PAREXEL experts will be available at PAREXEL's booth for on-site executive briefings to discuss best practice approaches to strategic partnering. They will address how the Company provides biopharmaceutical companies a precise fit with its expertise throughout the endto-end product development process. Other capabilities that will be presented by PAREXEL to support accelerated development and commercialization programs include worldwide regulatory expertise, Phase I-IV clinical research services, eClinical technologies, and medical communications services as well as reimbursement and market access services.

Experts from Perceptive Informatics, a subsidiary of PAREXEL and the industry's leading eClinical solutions provider, will also be available to discuss changes in the way technology is used in clinical trials to streamline workflow and facilitate more effective and efficient trial management. Attendees that visit Perceptive's booth will be able to view demonstrations of Perceptive's eClinical Suite, which provides interoperability among systems, including the DataLabs® EDC solution, IMPACT® Clinical Trial Management System, and the ClinPhone® Randomization and Trial Supply Management (RTSM) technologies.

Details of the numerous sessions that will be chaired or presented by PAREXEL experts during the DIA Annual Meeting can be accessed at: For more information about PAREXEL visit, and for more information about Perceptive Informatics visit Information about DIA's 46th Annual Meeting can be found at

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 54 countries around the world, and has approximately 9,500 employees. For more information about PAREXEL International visit

This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated restructuring charge of approximately $24 million over the second, third, and fourth quarters of Fiscal Year 2010; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2010 as filed with the SEC on May 7, 2010 which "Risk Factors" discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.


Jennifer Baird, Senior Director of Public Relations

Gene Carozza/Kim Baker

PAREXEL International

PAN Communications

Tel: +781-434-4409

Tel: +978-474-1900



SOURCE PAREXEL International Corporation

Back to news